Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday lulv q

Tuesday

TuPeC4841 Development of survey instruments to quantify
HIV/AIDS impacts and response capacity at
school level: lessons from field testing in subSaharan Africa
G Schierhout, A Kinghorn, S Johnson, E McKay,
J Rugeiyamu (South Africa)
TuPeC4842 Anything for data! Ethics of HIV/AIDS research
with human "subjects"
B Biswas (India)
TuPeC4843 Evaluating the efficacy of therapies in
observational studies: marginal structural models
to estimate the causal effect of HAART on CD4
S R Cole, MA Hernan, J B Margolick, M Cohen,
A Munoz (United States)
TuPeC4844 Methods for estimating the optimal time of
HAART initiation
MA Herndn, S R Cole, A Philippakis, ] M Robins
(United States)
TuPeC4845 Estimation of attributable fractions for HIV
infection associated with particular modes of
transmission
S C Shiboski, N S Padian, D T Halperin,
K Page-Shafer (United States)
TuPeC4846 Strategies to improve follow-up rates in a drug
user cohort in northern Thailand
T Vonqchak', M H Razak', P Saokhieo',
K Wiboonnatakul', S Kawichai', J J]ittiwutthikarn',
V Suriyanon', D D Celentano2 (Thailand; 2United
States)
TuPeC4847 HIV vaccine trial participation and recruitment in
South Africa - concerns of medical professionals
in the western cape
K Moodley1, J M Barnes', E]anse van Rensburg',
L Myer2 (South Africa; 2United States)
TuPeC4848 Targeting recruitment of intravenous drug users
using ethnographic-spatial analyses
J Negron-Ayala (United States)
TuPeC4849 Predictive value of CD4 count and viral load for
disease progression in untreated HIV-infected
children
T Duong, on behalf of HIV Paediatric Prognostic
Markers Collaborative Study (United Kingdom)
TuPeC485o Exercise and HIV: a cochrane collaboration
systematic review
K O'Brien, S A Nixon, R Glazier, A Tynan, A Wilkins
(Canada)
TuPeC4851 Epidemiology of HIV in South Africa with its
epicenter in KwaZulu Natal
A N Smith, P Moodley (South Africa)
TuPeC4852 The HIV-Knowledge Project - HIV and AIDS
research literature: a sociohistorical analysis
M Baehr (United States)
TuPeC4853 The impact of fat redistribution symptoms on the
cost-effectiveness of antiretroviral therapy in H IVinfected adults
B R Schackman KA Freedberg, M C Weinstein,
P E Sax, E Losina, H Zhang, S ]Goldie
(United States)
TuPeC4854 Costs and Effectiveness of a syringe distribution
and exchange programme in a regional setting
] M Cabases E Sanchez, G Hualde (Spain)
TuPeC4855 Cost-effectiveness of salvage therapy with
delavirdine in NNRTI-naive patients failing indinavir
R Becker, I Shakur (United States)
TuPeC4856 A discrete-event simulation approach to
modelling disease progression and the cost
effectiveness of health care programmes in HIVinfected patients
P Sendi M Battegay (Switzerland)

TuPeC4857 Simultaneous run of the Bayer VERSANT HIV-1
version 3.0 and HCV bDNA version 3.0
quantitative assays on the semi-automated
System 340: Reliable Quantitation with cost
savings from labor and reagents
T Elbeik N Markowitz, P Nassos, K Uday, B Haller,
V Ng (United States)
TuPeC4858 Modification of CD4+ cell count measurement for
cost reduction and the improvement of
accessibility
S Nookhai, S Buranapraditkun, S Ubolyam,
S Sirivichayakul, K Ruxrungtham, P Phanuphak
(Thailand)
TuPeC4859 Implementation of laboratory quality assurance
programmes for HIV testing in resource limited
environments - a cost effectiveness analysis
VA Wilson', W Kitson-Piggott', T Tillett2,
R McLean' (Trinidad and Tobago; 2Belize)
TuPeC486o Cost-benefit analysis of a programme to prevent
mother-to-child transmission of HIV in
Mozambique
D Peffer N Osman, P Vaz (Mozambique)
TuPeC4861 Pharmaco-economics of Nucleic-acid Amplification
Testing (NAT) of Dutch blood donors for HIV
M J Postma, J M Bos, M van Hulst
(The Netherlands)
TuPeC4862 The cost-effectiveness of nevirapine use in
antenatal clinics in Africa Is significantly impaired
by lack of client uptake
M Sweat', K O'Reilly2, G Schmid, J Denison',
I de Zoysa2 ('United States; 2Switzerland)
TuPeC4863 The cost effectiveness of directly observed
therapy late in pregnancy for HIV-infected women
WA Grobman, PM Garcia (United States)
TuPeC4864 Risk factors for incident HIV infection among HIV
testers in Santos, Brazil: 1996-1999
K Alves', M M Caseiro2, R S Diaz2, A Hernandez',
M E Falcao2, B D Rawal', M CA Sucupira2,
M P Busch', TM S Vieira2, G Rutherford',
Page-Shafer' ('United States; 2Brazil)
TuPeC4865 Using STARHS to Estimate HIV-1 Incidence among
Patients Attending STD Clinics in Selected U.S.
Cities, 1997-1999
L Linley, D Withum, H Weinstock, J Mei, K Bell,
I Royalty, M Miller (United States)
TuPeC4866 Detection of recent infection and estimates of
HIV-1 incidence using an IgG capture BED-EIA
from a cross-sectional sample of injection drug
users (IDUs) in Bangkok
D J Hu', S Vanichseni2, PA Mock2, N L Young2,
T Dobbs', K Choopanya2, TD Mastro', B S Parekh'
('United States; 2Thailand)
TuPeC4867 Stable HIV incidence among injection drug users
in San Francisco, 1987 to 2001
A H Kral, K Shafer, TA Kellogg, E Riley, B R Edlin,
A R Moss, M P Busch, W McFarland
(United States)
TuPeC4868 STARHS test shows HIV transmission continuing
in UK despite widespread HAART
G Murphy, I V Parry, L Flordan, A Charlet, B N Gill
(United Kingdom)
TuPeC4869 HIV incidence is elevated among persons who
have previously tested several times, San
Francisco, USA
TA Kellogg, L Loeb, I Dilley, B Adler, I Rinaldi,
W C McFarland (United States)

110

Final Program